AU2019902712A0 - Inhibitors and use thereof in cancer treatment - Google Patents

Inhibitors and use thereof in cancer treatment

Info

Publication number
AU2019902712A0
AU2019902712A0 AU2019902712A AU2019902712A AU2019902712A0 AU 2019902712 A0 AU2019902712 A0 AU 2019902712A0 AU 2019902712 A AU2019902712 A AU 2019902712A AU 2019902712 A AU2019902712 A AU 2019902712A AU 2019902712 A0 AU2019902712 A0 AU 2019902712A0
Authority
AU
Australia
Prior art keywords
inhibitors
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019902712A
Inventor
Robert Baxter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Filing date
Publication date
Application filed by University of Sydney filed Critical University of Sydney
Publication of AU2019902712A0 publication Critical patent/AU2019902712A0/en
Priority to PCT/AU2020/050779 priority Critical patent/WO2021016667A1/en
Priority to US17/628,061 priority patent/US20220259265A1/en
Abandoned legal-status Critical Current

Links

AU2019902712A 2019-07-30 2019-07-30 Inhibitors and use thereof in cancer treatment Abandoned AU2019902712A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/AU2020/050779 WO2021016667A1 (en) 2019-07-30 2020-07-30 Inhibitors and use thereof in cancer treatment
US17/628,061 US20220259265A1 (en) 2019-07-30 2020-07-30 Inhibitors and Use Thereof in Cancer Treatment

Publications (1)

Publication Number Publication Date
AU2019902712A0 true AU2019902712A0 (en) 2019-08-15

Family

ID=

Similar Documents

Publication Publication Date Title
EP3250609A4 (en) Il13ra alpha 2 binding agents and use thereof in cancer treatment
EP4066837A4 (en) Use of bi853520 in cancer treatment
EP3796920A4 (en) Trna/pre-mirna compositions and use in treating cancer
IL281999A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
EP3639829A4 (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug
EP3430057A4 (en) Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
EP3487492A4 (en) Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
EP3525791A4 (en) Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
EP3741748A4 (en) Compound and use thereof in medicine
EP3937980A4 (en) Modified micrornas and their use in the treatment of cancer
EP3960766A4 (en) Tumor therapeutic agent and use thereof
EP4038222A4 (en) Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4039679A4 (en) Novel compound and use thereof in treating autoimmune diseases
EP3753579A4 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
EP3654967A4 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
EP3648756A4 (en) Statin compositions and methods for use in treating synucleinopathies
EP3891123A4 (en) Oligo-benzamide analogs and their use in cancer treatment
EP4051669A4 (en) Ssao inhibitors and use thereof
AU2019902712A0 (en) Inhibitors and use thereof in cancer treatment
EP3999092A4 (en) Combination cancer therapy agents and methods
EP3833352A4 (en) Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers
EP3758694A4 (en) Bexarotene derivatives and their use in treating cancer
EP3946313A4 (en) Plk1 inhibitors and psa levels in prostate cancer
EP3955943A4 (en) Gmci and ddri combination therapy for treating cancer